Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source
No articles found.
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
At Achillion, we are driven to transform the lives of patients and families affect...
At Achillion, we are driven to transform the li...
Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...
Celsion Corporation is a fully integrated bioph...
We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a n...
We are a clinical stage biopharmaceutical compa...
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical compa...
Recro Pharma (NASDAQ: REPH) is a revenue genera...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinicalâstage biopharmaceutical c...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a c...
Intercept is a biopharmaceutical company focused on the development and commercial...
Intercept is a biopharmaceutical company focuse...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the...
Ritter Pharmaceuticals, Inc. develops novel the...
Join the National Investor Network and get the latest information with your interests in mind.